Scleroderma, Systemic

The supplied grounding does not identify a single cause or definitive aetiology. It indicates that autoimmunity and vasculopathy characteristically precede fibrosis in systemic sclerosis. Beyond that, no specific causal trigger is supported here.

Systemic sclerosis is described as a prototypic multisystem fibrotic disorder in which fibrosis affects multiple organs rather than a single tissue. The grounding emphasizes that autoimmunity and vasculopathy occur before fibrosis, and that diseased small blood vessels are a key feature. Fibrosis is the major process underlying morbidity and mortality, but the supplied material does not support a more detailed mechanism.

The supplied grounding does not provide specific risk factors for developing systemic sclerosis. It does support that the disease is associated with autoimmunity and vasculopathy as characteristic early features. No additional demographic, environmental, or clinical risk factors are supported here.

Treatment is described at the level of immunomodulatory therapy, with cyclophosphamide appearing as a co-studied drug. The EULAR update indicates that management is based on evidence across multiple interventions, but the supplied abstract does not list specific recommendations. The grounding also notes emerging immune-cell approaches such as CD19-targeting CAR-T therapy in refractory autoimmune rheumatic disease, including systemic sclerosis, but this is presented as investigational rather than established standard care.